Continuity plan
A personalized plan is developed before discharge.
Swiss roots. International expertise. Personal care, delivered with privacy and discretion.
Skip to contentClinical resource
Oman's new rehabilitation capacity raises a question relevant to families choosing care locally or abroad: who measures recovery after the residential stay?

Transition and aftercare
A personalized plan is developed before discharge.
Therapeutic, psychiatric, and local care is coordinated.
Risk, sleep, work, relationships, routines, and family remain in view.
Three months of personalized aftercare are included within the current private residential program; format and frequency are confirmed in the individual plan.
A new rehabilitation bed is a tangible investment. Sustained recovery is harder to count. Oman’s expansion of addiction treatment creates a useful moment to ask what happens during care and after a person returns home. For families considering treatment across borders, the comparison should concern complete pathways, not simply local versus international destinations.
April 16, 2026: the Ministry of Health announcement opening Al Salwa Hospital in Sohar.
30 beds: capacity described for the first phase.
25 beds: a planned second-phase detoxification department. Planned beds are not confirmed operational capacity.
Several weeks to six months: the described range for individualized rehabilitation programs, with discharge and follow-up coordination. This is not a recommended duration for every patient. [1]
This is a capacity comparison, not a patient count or clinical result. The figures should not be added and labeled current operating capacity. Source: Ministry of Health. [1]
New facilities matter because they describe a change in provision. The next evidence should connect that provision with the people assessed, admitted, treated, and followed afterward.
A bed count alone cannot establish symptom improvement, access to appropriate interventions, or the durability of recovery.
A new residence, a larger team, or more appointments may change availability and experience. None automatically quantifies clinical benefit.
Families should apply the standard consistently. Public services should not face demanding outcome questions while an expensive private program is evaluated only through testimonials.
Ask how the proposed setting fits assessed needs, what is delivered, and how progress is reviewed. The facilities are part of the offer, not a substitute for the clinical rationale.
A 2021 review found support for continuing care in substance-use treatment, while describing generally modest pooled benefits and variation between interventions. More active engagement and longer continuing-care approaches sometimes produced more consistent results. [2]
The review does not establish one ideal program for everybody or evaluate an Omani hospital. Evidence for a treatment component also does not automatically validate an entire commercial package.
A provider should distinguish what draws on established research from what has been evaluated in its own patients. An individualized plan can be clinically appropriate without a definitive comparative trial, provided the evidence is described honestly.
WHO and UNODC’s international standards describe evidence-based, ethical treatment systems across different needs and settings. They are not a league table of countries or a certificate guaranteeing a provider’s results. [3]
Use such frameworks to ask better questions about assessment, treatment, consent, and continuity. They should not replace the individual clinical decision or become a general claim of superiority.
| Stage | Useful measure | Limit |
|---|---|---|
| Availability | Operational capacity and eligibility | Does not establish care received |
| Access | Assessment and treatment-start intervals | Not clinical improvement |
| Engagement | Starts, completions, transfers, departures | An ending may be a planned transfer |
| Discharge | Health measures and patient goals | Not evidence of durability |
| Follow-up | Later health, functioning, and treatment | Respondents may not represent all admissions |
The Al Salwa announcement describes a partnership involving public bodies, a healthcare company, and supporting funding. That identifies an organizational model, not proof that one ownership structure produces better recovery. [1]
A fair comparison needs compatible patients, interventions, and outcomes. Services may differ in severity, substances involved, co-occurring conditions, and eligibility.
Costs also need a defined scope. A fee may exclude travel, continuing care, or unpaid family support. A legitimate preference for privacy or convenience does not itself demonstrate greater effectiveness.
A report should identify everyone it tried to contact and how many supplied an outcome. A favorable result among respondents is not automatically the result among everybody admitted.
Missing observations are unknown, not automatic relapse. A patient moving between countries may have transferred to another clinician. Where consent and data arrangements allow, that differs from completely unknown status.
Reports should also describe how outcomes were measured and what care continued. A return to treatment could indicate deterioration, timely help-seeking, or planned maintenance. The clinical context changes its meaning.
The announcement supports comparison between opened and planned phases. It does not establish a national addiction prevalence estimate, a citizen-versus-expatriate outcome, or a ranking of treatment destinations.
The Ministry’s Al Masarra Hospital information separately describes psychiatric, addiction, and community services, including support after hospital treatment. That provides service context, not a comparable longitudinal patient dataset. [4]
The useful next study would follow a defined group through care transitions. A national dataset, provider report, and original survey could each contribute, but should keep their separate populations and purposes.
Families considering care outside Oman may value specialist expertise, language, privacy, or time away from regular responsibilities. Those priorities should be discussed without assuming overseas care is better.
Travel can change who reviews medication, arranges follow-up, or responds to deteriorating symptoms. Resolve those responsibilities before admission where possible.
For a business owner, returning home may also mean resuming decisions and family responsibilities. For another patient, work may not be an immediate goal. Outcome measurement should allow both rather than define recovery as the fastest return to a demanding role.
| Decision | Information to obtain |
|---|---|
| Clinical suitability | Assessment, scope, exclusions, and co-occurring care |
| Continuity | Named responsibility for handover and review |
| Privacy | Purpose and consent for information sharing |
| Progress | Baseline measures, review dates, and patient goals |
| Evidence | Observed outcomes, eligible sample, and missing follow-up |
| Practical access | Language, travel, and receiving appointments |
This is a proposed discussion framework, not a validated clinic rating or an evaluation of Al Salwa Hospital. THE BALANCE should answer the same questions about its own pathway.
A recommendation to contact a professional differs from an accepted handover. The patient should know which arrangements are confirmed and which remain suggestions.
The range of several weeks to six months in the announcement describes individualized programs. It does not establish that longer stays always work better or prescribe a duration for a particular person.
Ask which goals justify the initial plan and what would prompt adjustment. A large budget should not replace reassessment, just as a short package should not force an unsuitable end to needed care.
Where clinical responsibilities cross countries, verify professional requirements and realistic access rather than rely on a broad worldwide-aftercare promise.
No source here establishes a recovery rate for the newly announced facility or a special outcome for HNW Omani patients. The opening is a service development, not a controlled trial. The continuing-care literature supports defined approaches rather than every program carrying that label.
The outcome is a life, not a bed-day. New capacity deserves attention, and the next reporting step should connect it to appropriate treatment and longer-term progress. For families, the decisive question is who remains involved and what happens when the setting changes.
Key distinction: thirty beds were described in the opened first phase; twenty-five detoxification beds were planned, not confirmed operational.
Outcome caveat: capacity and program duration do not establish recovery.
Suggested attribution: THE BALANCE analysis of Oman’s service announcement and continuing-care evidence.
This narrative analysis preserves the distinction between completed and planned phases in the Arabic ministry announcement. It uses no patient records or proprietary outcomes. The reporting framework is proposed analysis, not observed service performance.
YOU MAY FIND THESE HELPFUL
Clear information is framed around complex and co-occurring presentations.
Assessment remains essential because needs and risks differ from person to person.
A confidential conversation can help clarify the most appropriate route forward.
Your admissions team


A confidential first conversation can help clarify the presentation and whether our setting is appropriate.